ClinicalTrials.gg
CompletedNCT01378988Updated Jul 24, 2015Results posted

Phase II Pharmacokinetic and Pharmacodynamic Study of DEX in Subjects Aged 12 Months Through <24 Months

A Phase 2 interventional study of Dexmedetomidine in Sedation and Pain, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 1 site in United States. Open to participants aged 12 Months to 23 Months. Per ClinicalTrials.gov, last updated 2015-07-24.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
12 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies testing dexmedetomidine in Pain — 11 open to participants now, 12 under way, 2 of them phase 3. Dexmedetomidine · Pain.

Enrollment
60th of 63
5 · median 70
Started
2011
with 3 others
Phase 2
8 of 64
1 open now
Registered
6th of 64
by date

Among the 64 studies testing dexmedetomidine in Pain, this one is the 60th largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2011, is one of 8 in phase 2, and was the 6th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.

Browse Pain studies →

Open to participants now

11 of the 64 studies testing dexmedetomidine in Pain are open now, in 7 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.

This study: 12 Months to 23 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing dexmedetomidine in Pain, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the pharmacokinetic, pharmacodynamic, and safety of dexmedetomidine at 2 different dose levels in pediatric subjects, aged 12 months through \<24 months, administered as an intravenous loading dose followed by continuous infusion for a minimum of 6 hours and up to 24 hours in an intensive care setting.

Read the detailed description

Phase II, randomized, open-label, single-center, study evaluating the pharmacokinetics and pharmacodynamics of dexmedetomidine in pediatric subjects across two dose levels (Dose Level 1 consists of a 0.7 mcg/kg loading dose immediately followed by a 0.5 mcg/kg/hr maintenance infusion; Dose Level 2 consists of a 1.0 mcg/kg loading dose immediately followed by a 0.75 mcg/kg/hr maintenance infusion). The study population will consist of intubated and mechanically ventilated pediatric subjects who require sedation in an intensive care setting for a minimum of 6 hours but not to exceed 24 hours. Subjects eligible for enrollment are 12 months to \<24 months of age.

03

Conditions studied

  • Sedation
  • Pain

Browse trials for

04

Who can participate

Ages eligible
12 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject is 12 months to \<24 months of age at screening.
  2. Subject is intubated and mechanically ventilated in an intensive care setting and is anticipated to require a minimum of 6 hours of continuous IV sedation.
  3. Subject has adequate renal function, defined as: Serum creatinine ≤1.0 mg/dL.
  4. The subject's parent(s) or legal guardian(s) must voluntarily sign and date the document approved by the Institutional Review Board.

Exclusion criteria

Exclusion Criteria:

  1. Pediatric subjects with neurological conditions that prohibit an evaluation of sedation such as:

    • Diminished consciousness from increased intracranial pressure
    • Extensive brain surgery (surgery requiring intracranial pressure monitor)
    • Diminished cognitive function per Principal Investigator (PI) discretion
    • Subjects with immobility from neuromuscular disease or continuous infusion of neuromuscular blocking agents.
  2. Subjects with second degree or third degree heart block unless subject has a permanent pacemaker or pacing wires are in situ.
  3. Subjects who have hepatic impairment as defined by a serum glutamic-pyruvic transaminase/ (SGPT/ALT) >90 U/L at the time of screening.
  4. Subjects who have hypotension, based on repeat assessments within 15 minutes preceding the start of study drug, defined as: Systolic blood pressure (SBP) \<70 mmHg.
  5. Pre-existing bradycardia based on repeated assessments within 15 minutes preceding the start of study drug, defined as: Heart rate (HR) \<70 bpm.
  6. Subject who have acute thermal burns involving more than 15 percent total body surface area.
  7. Subjects who have a known allergy to dexmedetomidine, midazolam or fentanyl.
  8. Subject who has received dexmedetomidine within 15 hours prior to the start of study drug.
  9. Subjects with a that is \<72 hours.
  10. Subjects that are expected to have hemodialysis (continuous hemofiltration), peritoneal dialysis or extracorporeal membrane oxygenation (ECMO) treatments within 48 hours prior to the start of study drug or during the duration of the study.
  11. Subjects who have been treated with α-2 agonists/antagonists within 2 weeks.
  12. Subjects with a spinal cord injury above T5 (5th Thoracic Vertebra).
  13. Subjects who have received another drug as part of an investigational drug study within the past 30 days.
  14. Subjects who, in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of this clinical study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Dose level 1

    Dexmedetomidine 0.7 mcg/kg loading dose and 0.5 mcg/kg/hr maintenance infusion

    Drug: Dexmedetomidine

  • Experimental
    Dose level 2

    Dexmedetomidine 1.0 mcg/kg loading dose and 0.75 mcg/kg/hr maintenance infusion

    Drug: Dexmedetomidine

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve (AUC0-∞)

    Area under the plasma concentration-time curve of dexmedetomidine at 0 to Infinity hours

    Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI

  2. Observed Peak Plasma Concentration (Cmax)

    Maximum observed concentration of dexmedetomidine in plasma

    Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI

  3. Steady State Concentration (Css)

    Concentration of dexmedetomidine at steady state in plasma

    Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI

  4. Terminal Elimination Half-life (t1/2)

    Terminal elimination half-life of dexmedetomidine. Half-life is the time required for plasma concentration of the drug to decrease by 50%.

    Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI

  5. Time to Reach Maximum Plasma Concentration (Tmax)

    Observed time to reach maximum plasma concentration of dexmedetomidine, expressed in hours

    Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI

  6. Weight-Adjusted Plasma Clearance (CLw)

    Weight-Adjusted Plasma Clearance of dexmedetomidine after intravenous administration.

    Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI

  7. Plasma Clearance (CL)

    Clearance of dexmedetomidine after intravenous administration. Clearance is the rate at which the drug is removed from the plasma after the dose.

    Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI

  8. Volume of Distribution (Vd)

    Volume of distribution of dexmedetomidine after intravenous administration. Volume of distribution measures how much the drug spreads through the body after the dose.

    Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI

  9. Weight-Adjusted Volume of Distribution (Vdw)

    Weight-Adjusted Volume of distribution of dexmedetomidine after intravenous administration.

    Time frame: 30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI

  10. Average Total Faces, Legs, Activity, Cry, and Consolability (FLACC) Score

    FLACC scale is a 5 category observational measure to assess pediatric pain on face, legs, activity, cry and consolability. Responses in each category are scored between 0 to 2 (0 = normal, relaxed to 2 = upset, rigid), for a maximum total score of 10.

    Time frame: Prior to loading dose and every hour during the maintenance infusion; within 5 minutes after any fentanyl administration during DEX infusion or every 4 hours in case of continuous fentanyl infusion; within 5 minutes prior and after titration of fentanyl

  11. Absolute Time That Subject is in UMSS Range 2-4 During Treatment Period

    The level of sedation will be assessed using the University of Michigan Sedation Scale (UMSS). Score 0 (awake/alert); Score 1 (sleepy/responds appropriately); Score 2 (somnolent/arouses to light stimuli); Score 3 (deep sleep/arouses to deeper physical stimuli); Score 4 (unarousable). The UMSS scores obtained just prior the loading dose (LD) and 5 and 10 minutes during LD; 0, 5, 10, 15, 30, and 60 minutes and thereafter every 4 hours of the maintenance infusion; within 5 minutes of obtaining each pharmacokinetic sample; within 5 minutes prior and after any midazolam rescue during dexmedetomidine infusion period.

    Time frame: During the treatment (6 to 24 hours)

  12. Number of Subjects Who Received Rescue Medication for Sedation and Analgesic

    Participants who received rescue medication midazolam for sedation and/or fentanyl for analgesic during study drug Infusion

    Time frame: During the treatment (6 to 24 hours)

07

Results

Posted Jul 24, 2015

Participant flow

Participant flow — Overall Study
MilestoneDose Level 1Dose Level 2
Started23
Completed23
Not completed00

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve (AUC0-∞)

Area under the plasma concentration-time curve of dexmedetomidine at 0 to Infinity hours

Time frame:
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Reported as:
Mean · picogram*hour per millilitre
Area Under the Plasma Concentration-time Curve (AUC0-∞)
picogram*hour per millilitreDose Level 1Dose Level 2
Area Under the Plasma Concentration-time Curve (AUC0-∞)4639.17 ± 4058.189314203.544 ± 13051.6850
PrimaryObserved Peak Plasma Concentration (Cmax)

Maximum observed concentration of dexmedetomidine in plasma

Time frame:
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Reported as:
Mean · picogram per millilitre
Observed Peak Plasma Concentration (Cmax)
picogram per millilitreDose Level 1Dose Level 2
Observed Peak Plasma Concentration (Cmax)4499.925 ± 5826.736711737.387 ± 3549.7923
PrimarySteady State Concentration (Css)

Concentration of dexmedetomidine at steady state in plasma

Time frame:
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Reported as:
Mean · picogram per millilitre
Steady State Concentration (Css)
picogram per millilitreDose Level 1Dose Level 2
Steady State Concentration (Css)752.298 ± 658.08482303.277 ± 2116.4895
PrimaryTerminal Elimination Half-life (t1/2)

Terminal elimination half-life of dexmedetomidine. Half-life is the time required for plasma concentration of the drug to decrease by 50%.

Time frame:
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Reported as:
Mean · Hours
Terminal Elimination Half-life (t1/2)
HoursDose Level 1Dose Level 2
Terminal Elimination Half-life (t1/2)1.958 ± 0.37652.260 ± 1.2205
PrimaryTime to Reach Maximum Plasma Concentration (Tmax)

Observed time to reach maximum plasma concentration of dexmedetomidine, expressed in hours

Time frame:
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Reported as:
Mean · Hours
Time to Reach Maximum Plasma Concentration (Tmax)
HoursDose Level 1Dose Level 2
Time to Reach Maximum Plasma Concentration (Tmax)0.083 ± 0.00.283 ± 0.3464
PrimaryWeight-Adjusted Plasma Clearance (CLw)

Weight-Adjusted Plasma Clearance of dexmedetomidine after intravenous administration.

Time frame:
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Reported as:
Mean · Litre per Hours per Kilogram
Weight-Adjusted Plasma Clearance (CLw)
Litre per Hours per KilogramDose Level 1Dose Level 2
Weight-Adjusted Plasma Clearance (CLw)1.292 ± 1.13000.617 ± 0.3815
PrimaryPlasma Clearance (CL)

Clearance of dexmedetomidine after intravenous administration. Clearance is the rate at which the drug is removed from the plasma after the dose.

Time frame:
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Reported as:
Mean · Litre per Hour
Plasma Clearance (CL)
Litre per HourDose Level 1Dose Level 2
Plasma Clearance (CL)12.192 ± 9.57705.836 ± 2.9357
PrimaryVolume of Distribution (Vd)

Volume of distribution of dexmedetomidine after intravenous administration. Volume of distribution measures how much the drug spreads through the body after the dose.

Time frame:
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Reported as:
Mean · Litre
Volume of Distribution (Vd)
LitreDose Level 1Dose Level 2
Volume of Distribution (Vd)31.845 ± 20.435115.780 ± 3.5461
PrimaryWeight-Adjusted Volume of Distribution (Vdw)

Weight-Adjusted Volume of distribution of dexmedetomidine after intravenous administration.

Time frame:
30 minutes prior to loading dose (LD); 5 minutes before finishing LD; 0.5, 1, 2 and 4-6 hours during maintenance infusion (MI); 30 minutes prior (within 24 hours of start of MI) and 10 minutes, 0.5, 1, 2, 4 and 10 hours end of MI
Reported as:
Mean · Litre per Kilogram
Weight-Adjusted Volume of Distribution (Vdw)
Litre per KilogramDose Level 1Dose Level 2
Weight-Adjusted Volume of Distribution (Vdw)3.343 ± 2.49101.590 ± 0.6201
PrimaryAverage Total Faces, Legs, Activity, Cry, and Consolability (FLACC) Score

FLACC scale is a 5 category observational measure to assess pediatric pain on face, legs, activity, cry and consolability. Responses in each category are scored between 0 to 2 (0 = normal, relaxed to 2 = upset, rigid), for a maximum total score of 10.

Time frame:
Prior to loading dose and every hour during the maintenance infusion; within 5 minutes after any fentanyl administration during DEX infusion or every 4 hours in case of continuous fentanyl infusion; within 5 minutes prior and after titration of fentanyl
Reported as:
Mean · units on a scale
Average Total Faces, Legs, Activity, Cry, and Consolability (FLACC) Score
units on a scaleDose Level 1Dose Level 2
Average Total Faces, Legs, Activity, Cry, and Consolability (FLACC) Score1.575 ± 2.22743.220 ± 2.1707
PrimaryAbsolute Time That Subject is in UMSS Range 2-4 During Treatment Period

The level of sedation will be assessed using the University of Michigan Sedation Scale (UMSS). Score 0 (awake/alert); Score 1 (sleepy/responds appropriately); Score 2 (somnolent/arouses to light stimuli); Score 3 (deep sleep/arouses to deeper physical stimuli); Score 4 (unarousable). The UMSS scores obtained just prior the loading dose (LD) and 5 and 10 minutes during LD; 0, 5, 10, 15, 30, and 60 minutes and thereafter every 4 hours of the maintenance infusion; within 5 minutes of obtaining each pharmacokinetic sample; within 5 minutes prior and after any midazolam rescue during dexmedetomidine infusion period.

Time frame:
During the treatment (6 to 24 hours)
Reported as:
Mean · Hours
Absolute Time That Subject is in UMSS Range 2-4 During Treatment Period
HoursDose Level 1Dose Level 2
Absolute Time That Subject is in UMSS Range 2-4 During Treatment Period3.6 ± 3.485.8 ± 0.38
PrimaryNumber of Subjects Who Received Rescue Medication for Sedation and Analgesic

Participants who received rescue medication midazolam for sedation and/or fentanyl for analgesic during study drug Infusion

Time frame:
During the treatment (6 to 24 hours)
Reported as:
Number · participants
Number of Subjects Who Received Rescue Medication for Sedation and Analgesic
participantsDose Level 1Dose Level 2
Midazolam for sedation11
Fentanyl for Analgesic12

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dose Level 1—0/2 (0%)0/2 (0%)
Dose Level 2—0/3 (0%)1/3 (33.3%)
Most frequent other events
Most frequent other events
EventDose Level 1Dose Level 2
PyrexiaGeneral disorders0/21/3
AtelectasisRespiratory, thoracic and mediastinal disorders0/21/3

Baseline characteristics

Safety Evaluable Population consisted of all subjects who received any amount of study drug.

Age, Continuous
Age, Continuous(years)Dose Level 1Dose Level 2Total
Mean1.43 ± 0.3121.45 ± 0.2741.44 ± 0.249
Sex: Female, Male
Sex: Female, Male(Participants)Dose Level 1Dose Level 2Total
Female112
Male123
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dose Level 1Dose Level 2Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White134
More than one race000
Unknown or Not Reported101
08

Study locations

1 site
  • Children's Hospital of Pittusburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2015, 3 years 11 months after primary completion. A results delay was requested in Sep 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2011
First posted
Jun 23, 2011
Start
Jun 2011
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results delay requested
Sep 12, 2012
Results first posted
Jul 24, 2015
Last update
Jul 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01378988
Responsible party
Sponsor
First posted
Jun 23, 2011
Start date
Jun 2011
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Jul 24, 2015
Last update
Jul 24, 2015

Study contacts

Constantinos Chrysostomou, MD
principal investigator · Children's Hospital of Pittusburgh of UPMC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion